BBNX · NASDAQ
Beta Bionics, Inc.
$19.16 -0.19 (-0.98%)
Company overview
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc.
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- Exchange
- NASDAQ
- Market cap
- $862M
- Employees
- 352
- Headquarters
- Irvine, CA
- Website
- betabionics.com
- CEO
- Sean T. Saint
- Listed
- January 30, 2025
- P/E
- -12.69
- Dividend yield
- 0.00%
Company financials
- Revenue
- $110M
- Gross profit
- $63M
- Operating income
- -$77.3M
- EBITDA
- -$69.4M
- Net income
- -$66.4M
- EPS
- -$1.51
- Total assets
- $304M
- Total debt
- $6.9M
- Gross margin
- 57.15%
- Net margin
- -60.27%
- Earnings yield
- -7.88%
BBNX
1D
NASDAQ
O18.28H19.38L18.23C19.35+0.95 (+5.16%)Vol279.33K